Aeglea BioTherapeutics. has filed a patent for compositions and methods to treat cancers lacking argininosuccinate synthetase. The invention involves an arginase protein with enhanced catalytic activity, such as human Arginase I with amino acid substitutions and a cobalt metal cofactor. GlobalData’s report on Aeglea BioTherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Aeglea BioTherapeutics, Affinity chromatography for antibodies was a key innovation area identified from patents. Aeglea BioTherapeutics's grant share as of January 2024 was 40%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cancer with modified arginase protein and cobalt
The patent application (Publication Number: US20240009283A1) discloses a protein comprising the amino acid sequences of human Arginase I or Arginase II with a non-native metal cofactor, specifically cobalt. The protein can also include truncated sequences of Arginase I or Arginase II, lacking specific amino acids from the wild-type sequence. Additionally, the protein may display enhanced hydrolysis of Arginine, resulting in increased catalytic efficiency compared to native human Arginase I or Arginase II. This enhanced activity is achieved through amino acid substitutions at the metal binding site, leading to a kcat/Km value between 400 mM-1 s-1 and 4,000 mM-1 s-1 at pH 7.4.
Furthermore, the patent application covers nucleic acids encoding the described proteins, vectors containing these nucleic acids, host cells expressing the proteins, and fusion proteins incorporating the described proteins with heterologous peptide segments. The application also includes methods for treating arginine auxotrophic cancers in human patients by administering formulations containing the disclosed proteins. The formulations can be administered through various routes, including topical, intravenous, intradermal, and oral, among others. Additionally, pharmaceutical formulations comprising the disclosed proteins and pharmaceutically acceptable excipients are also encompassed in the patent application, highlighting the potential therapeutic applications of these engineered proteins in cancer treatment.
To know more about GlobalData’s detailed insights on Aeglea BioTherapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
